Sodium Hyaluronate Combined with Pranolprofen Improve Visual Function and Reduce Inflammation in Patients with Dry eye

Abstract

Abstract Objective The aim of this study was to investigate the clinical application of sodium hyaluronate combined with pranoprofen in patients with dry eye.Methods This study’s subjects were 117 patients with dry eye who were diagnosed and treated at our hospital between March 2020 and May 2022. They were divided into three groups based on the therapy methods: sodium hyaluronate (SH) group (N = 39, treated with SH), pranoprofen group (N = 39, treated with pranoprofen), and joint group (N = 39, treated with SH combined with pranoprofen). The clinical efficacy of different treatment methods on patients was evaluated. The symptoms (Ocular Surface Disease Index scale), tear film stability (tear film rupture time, tear film secretion volume, and corneal fluorescein staining), and visual function (visual contrast sensitivity) of patients were assessed among the groups. The levels of tear inflammatory factors, including C-reactive protein (CPR), tumor necrosis factor-α (TNF-α), interferon-γ (IFN-γ) and interleukin-1β (IL-1β) were tested by enzyme-linked immunosorbent assay.Results The effective rates of dry eye in the SH group, the pranoprofen group and the joint group were 79.49%, 74.36% and 94.87%, respectively, with the joint group showing a significantly higher rate than the other groups (P < 0.05). After treatment, the tear film rupture time and tear film secretion of the three groups were prominently increased than those before treatment (P < 0.05), and the joint group was significantly higher than that of the SH group (P < 0.05) and the pranoprofen group (P < 0.05). The corneal fluorescein staining and dry eye symptom scores of the three groups after treatment were dramatically lower than those before treatment (P < 0.05), and the joint group showed significant lower scores than the other groups (P < 0.001). After treatment, the visual contrast sensitivity (12c/d, 18c/d and 24c/d) of the three groups were sensibly higher than before treatment (P < 0.05), and the joint group exhibited higher visual contrast sensitivity compared with other groups (P < 0.001). The CPR, TNF-α, IFN-γ and IL-1β levels of the three groups were notably decreased after treatment (P < 0.05), and the levels of these factors in joint group were dramatically decreased compared with other groups (P < 0.001). The three groups displayed reduced levels of CPR, TNF-α, IFN-γ and IL-1β after treatment (P < 0.05), and the joint group showed significant lower levels compared with other groups (P < 0.001).Conclusion SH combined with pranoprofen demonstrated obvious clinical efficacy in the treatment of dry eye, and the curative effect was superior to single drug use. It significantly improved clinical symptoms, tear film stability, and visual function, as well as reducing patients’ inflammatory response, which had a high clinical promotion value.